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Leptin Inhibits Bone Formation
through a Hypothalamic Relay:
A Central Control of Bone Mass
bone remodeling. For instance, gonadal failure and the
sex steroid deficiency accompanying it stimulate the
bone resorption phase of bone remodeling (Riggs and
Melton, 1986). Moreover, novel regulators of bone re-
sorption acting in a systemic manner have been identi-
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National Cancer Institute In contrast to what has been learned about bone re-
Bethesda, Maryland 20892 sorption, we still know very little about the genetic con-
trol of bone formation by the osteoblasts. The existence
of a systemic or endocrine regulation of bone resorption
Summary suggests that a similar mechanism may control bone
formation, although it has not been identified geneti-
Gonadal failure induces bone loss while obesity pre- cally. The identification of systemic regulators of bone
vents it. This raises the possibility that bone mass, formation, if they exist, is of paramount importance
body weight, and gonadal function are regulated by given the incidence and morbidity of low bone mass
common pathways. To test this hypothesis, we studied diseases and the current lack of anabolic therapies for
leptin-deficient and leptin receptor±deficient mice that these disorders.
are obese and hypogonadic. Both mutant mice have an To identify regulators of bone formation, we isolated
increased bone formation leading to high bone mass in a classical bone remodeling disease features allowing
despite hypogonadism and hypercortisolism. This
us to formulate a hypothesis testable genetically and
phenotype is dominant, independent of the presence
physiologically. Osteoporosis, the most frequent bone
of fat, and specific for the absence of leptin signaling.
remodeling disease, is defined by a low bone mass and
There is no leptin signaling in osteoblasts but intrace-
a high risk of fractures (Consensus Development Confer-rebroventricular infusion of leptin causes bone loss in
ence, 1993). It is caused by a relative increase of boneleptin-deficient and wild-type mice. This study identi-
resorption over bone formation. Two clinical character-fies leptin as a potent inhibitor of bone formation act-
istics of osteoporosis can be used to propose a hypothe-ing through the central nervous system and therefore
sis. First, osteoporosis invariably develops following go-describes the central nature of bone mass control and
nadal failure (Riggs and Melton, 1986; Riggs et al., 1998).its disorders.
Second, obesity protects from osteoporosis through an
unknown mechanism (Felson et al., 1993; Tremollieres et
Introduction
al., 1993; Ravn et al., 1999). In molecular terms, together
these two observations suggest that bone mass, body
Bone mass is regulated through bone remodeling. The
weight, and gonadal function could be regulated by simi-fundamental importance of this process in vertebrate
lar molecules.biology is illustrated by the fact that osteoporosis, a
Leptin is a small polypeptide hormone secreted pri-bone remodeling disease, is the most common disease
marily by the adipocytes. It controls body weight and,in the Western Hemisphere (Cooper and Melton, 1996).
directly or indirectly, gonadal function following its bind-Bone remodeling is comprised of two well-defined cellu-
ing to a specific receptor located in the hypothalamuslar events that occur sequentially. There is first resorp-
(see Spiegelman and Flier, 1996 and Friedman and Ha-tion of preexisting bone by the osteoclasts then de novo
laas, 1998 for review). Accordingly, ob/ob and db/dbbone formation by the osteoblasts (Frost, 1969). The
mice that are deficient in leptin or its receptor, respec-two phases of bone remodeling occur in a balanced
tively, are obese and hypogonadic (Zhang et al., 1994;fashion in order to maintain bone mass within narrow
Tartaglia et al., 1995). This hypogonadism should leadlimits between the end of puberty and arrest of gonadal
to a low bone mass phenotype as gonadal failure favorsfunction.
bone resorption over bone formation (Riggs and Melton,The prevailing view is that bone remodeling is gov-
1986). The hypercortisolism of these animals is anothererned primarily by autocrine/paracrine mechanisms.
osteoporosis-favoring condition by inhibiting bone for-However, several lines of evidence suggest the involve-
mation (Reid, 1997; Ahima et al., 1999).ment of endocrine/systemic regulators in the control of
Instead, we show here that the absence of leptin sig-
naling in ob/ob and db/db mice results in a high bone§ To whom correspondence should be addressed (e-mail: karsenty@
mass (HBM) phenotype whose appearance precedesbcm.tmc.edu).
k These authors contributed equally to this work. the onset of obesity. ob/ob and db/db mice are identified
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Figure 1. High Bone Mass Phenotype in ob/
ob and db/db Mice
(A) X-ray analysis of vertebrae (vert.) and long
bones (femurs) of 6-month-old wt and ob/ob
mice.
(B) Histological analysis of bones of 3-month-
old (3 m.) and 6-month-old (6 m.) wt and ob/
ob mice. Mineralized bone matrix is stained
in black by the von Kossa reagent. Note the
increased number of black trabeculae in ob/
ob mice compared to wt littermates.
(C) Quantification of the increase in bone vol-
ume in ob/ob mice. BV/TV, bone volume over
trabecular volume. Gray bars, wt mice; black
bars, ob/ob mice.
(D) Three-point bending analysis of femurs
from wt, ob/ob, and wt ovariectomized (wt-
OVX) mice. The ob/ob mice have a higher
percentage of load to failure than wt ovariec-
tomized animals.
(E) Histological analysis of vertebrae of
6-month-old wt and db/db mice.
(F) Quantification of the increase in bone vol-
ume in db/db mice.
(G) Comparison of the hormonal profiles of
wt and ob/ob mice. ob/ob mice are hypercor-
tisolic. (PTH, pg/ml; thyroxin (T4), mg/dl; IGF1,
ng/ml; corticosterone, ng/ml.)
(H) Bone remodeling in absence of leptin sig-
naling. Despite the existence of hypogo-
nadism and hypercortisolism, two bone loss±
favoring conditions, ob/ob and db/db mice
have a high bone mass.
Asterisks indicate a statistically significant
difference between two groups of mice (p ,
0.05). Error bars represent SEM.
animal models in which hypogonadism and hypercorti- have a lower bone mass than wt littermates (Ahima et
al., 1996; Chehab et al., 1996; Ahima et al., 1997). Tosolism coexist with HBM. Histomorphometric and physi-
ologic analyses demonstrate that leptin is a selective determine if the obesity of the ob/ob mice could affect
their expected low bone mass phenotype, we performedinhibitor of bone formation. There is no evidence of leptin
signaling in osteoblasts, fat is not required for the devel- X rays of vertebrae and long bones of 6-month-old wt
and ob/ob mice. Surprisingly, the bones of the ob/obopment of this phenotype, but intracerebroventricular
infusion of leptin reverses completely the HBM pheno- mice appeared much denser than those of their wt lit-
termates (Figure 1A), demonstrating the presence of atype of the ob/ob mice and induces bone loss in wild-
type (wt) mice. These findings describe a central reg- higher amount of mineralized bone matrix. Given the
poor sensitivity of X rays to quantitate bone mass abnor-ulation of bone remodeling. This novel regulatory loop
describes a mechanism able to overcome the deleterious malities, this increased bone density was an indication
effects of gonadal failure and hypercortisolism on bone of a major change in bone architecture.
mass. These results should modify our understanding Histologic analyses performed in 3- and 6-month-old
of bone remodeling and of osteoporosis. mice showed the presence of many more thick trabecu-
lae in the bones of ob/ob mice compared to those of
wt mice (Figure 1B). The cortical bone was not affectedResults
(data not shown). Histomorphometric quantitation showed
a nearly 2-fold increase in trabecular bone volume inHigh Bone Mass Phenotype Despite Hypogonadism
ob/ob mice compared to wt littermates (Figure 1C). Thisand Hypercortisolism in ob/ob and db/db Mice
phenotype was observed in both sexes. The functionalWithout any known exception, hypogonadism induces
consequences of this increase in bone mass were ana-an increase in osteoclast number and in bone resorption
lyzed by comparing the biomechanical properties ofactivity; as a result, it leads to a low bone mass pheno-
long bones of 6-month-old ob/ob mice, wt mice, andtype (Riggs and Melton, 1986). Thus, the ob/ob mice
that have a hypogonadism of hypothalamic origin should wt mice that were ovariectomized (wt-ovx) for 4 months
Central Control of Bone Formation
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Figure 2. The High Bone Mass Phenotype of the ob/ob Mice Is Due to Leptin Deficiency, Not to Obesity
(A) Histological analysis of vertebrae of 1-month-old wt and ob/ob mice fed a low fat diet (LF diet). The body weight (B. Weight) is similar
between both groups of mice, but the bone volume (Bone Vol., BV/TV) is increased in ob/ob mice.
(B) Histological analysis of vertebrae of 3-month-old wt and ob/1 mice. While there is no difference in body weight, heterozygote mutant
mice have an increase in bone volume.
(C) Histological analysis of vertebrae of 6-month-old wt and Agouti yellow mutant mice (Ay/a). The body weight is higher in mutant mice, but
there is no difference in bone volume compared to wt mice.
(D) Histological analysis of vertebrae of 6-month-old wt mice fed a normal diet or a high fat (HF) diet. Bone volume was not increased in mice
fed HF diet despite a 50% increase in their body weight.
Underlined numbers indicate a statistically significant difference between experimental and control groups of mice (p , 0.05).
to mimic the hypogonadic status of the ob/ob mice. critical importance since hypercortisolism inhibits bone
formation and is the second most frequent cause ofUsing a three-point bending assay, failure load of the
bones from wt and ob/ob mice were indistinguishable bone loss after gonadal failure. Thus, the HBM pheno-
type of the ob/ob mice develops despite the coexistencebut significantly higher than the one observed in the
bones of wt-ovx mice (Figure 1D), indicating that leptin of two bone loss±favoring circumstances, hypogo-
nadism and hypercortisolism (Figure 1H). The unique-deficiency has a beneficial effect on the biomechani-
cal properties of the bones. We also analyzed the bones ness of this situation led us to explore its underlying
mechanisms.of the db/db mice that have an inactivating mutation
of the leptin receptor (Tartaglia et al., 1995). Like the
ob/ob mice, the db/db mice are obese and hypogonadic.
There was in db/db mice an increase in the number of The High Bone Mass Phenotype of the ob/ob Mice
Is Not Secondary to Obesitytrabeculae in both long bones and vertebrae similar to
that observed in ob/ob mice (Figure 1E and data not The HBM phenotype of the ob/ob and db/db mice could
be secondary either to a lack of leptin signaling or toshown), resulting in a 3-fold increase in bone volume
compared to wt mice (Figure 1F). This latter result dem- the obesity of these mice. To distinguish between these
two possibilities, we analyzed several additional groupsonstrates that leptin signals through its known receptor
to affect bone mass. of mutant mice. First, we took advantage of the fact that
a low fat diet postpones the appearance of obesity inTo determine whether the HBM phenotype of the ob/
ob mice could be explained by other endocrine abnor- ob/ob mice. ob/ob mice fed this low fat diet had a normal
weight at one month of age; nevertheless, they alreadymalities secondary to the absence of leptin signaling,
we measured in their serum the level of hormones whose had an HBM phenotype at that age (Figure 2A). Second,
we analyzed heterozygote leptin±deficient mice (ob/1)dysregulation affects bone mass (Figure 1G). ob/ob mice
had a normal level of parathyroid hormone, a hormone that are not obese; these animals also had an HBM
phenotype (Figure 2B). Third, we studied the bones ofwhose deficiency causes HBM. They also have nearly
normal IGF1 and thyroxin levels but a severe hypercorti- other mouse models of obesity that are not primarily
related to leptin signaling. Another genetic model ofsolism (Figure 1G and Ahima et al., 1999). This is of
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Figure 3. The Absence of Leptin Signaling
Causes an Increase in Osteoblast Function
(A) Calcein double labeling in 3-month-old wt
and ob/ob mice. The distance between the
two labels (white arrow) represents the rate
of bone formation. It is significantly increased
in ob/ob mice.
(B±F) The rate of bone formation is increased
in ob/ob mice (B) and db/db mice (D) 45%
and 70%, respectively, compared to wt lit-
termates. This increase occurs in the pres-
ence of a normal number of osteoblasts (C
and E) and in spite of the increased number
of osteoclasts due to their hypogonadism (F).
Empty bars, wt mice; black bars, ob/ob mice;
gray bars, db/db mice; 3 m., 3-month-old ani-
mals; 6 m., 6-month-old animals.
(G) Increased bone formation rate in fat-
restricted 1-month-old ob/ob mice and het-
erozygote ob/1 mice, which are not obese
(see body weights Figures 2A and 2B).
(H) wt mice fed a high fat diet, or Ay/a mice
that are overweight (see Figures 2C and 2D)
but not leptin deficient have a normal rate of
bone formation.
Asterisks indicate statistically significant dif-
ferences compared to control mice (p , 0.05).
Error bars represent SEM.
obesity, the Agouti yellow (Ay/a) mice (Herberg and absence of leptin signaling on osteoblast function using
the same control animals as above. One-month-old ob/Coleman, 1977), had a normal bone mass; the same
was true for wt mice fed with a high fat diet (Figures 2C ob animals that were fed a low fat diet and heterozygote
leptin±deficient mice, both lean, had a significant in-and 2D).
In summary, the existence of an HBM phenotype in crease in their rate of bone formation (Figure 3G). In
contrast, Ay/a mutant mice as well as wt mice fed a highob/ob mice prior to the appearance of obesity and
in ob/1 mice that are not obese as well as its absence in fat diet, two leptin-unrelated models of obesity, had
normal bone formation parameters (Figure 3H).leptin-unrelated models of obesity demonstrate that it
is the absence of leptin signaling, not the obesity, that
causes this HBM phenotype. Analysis of Osteoclast Function in ob/ob Mice
The coexistence of an HBM phenotype and of hypogo-
nadism was so exceptional that it raised the hypothesisIncreased Osteoblastic Function
in ob/ob and db/db Mice that bone resorption might be defective in these mice.
The increased urinary elimination of deoxypyridinolineThe increase in bone mass in these mice could be due
to an increase in osteoblastic bone formation, to a de- crosslinks (Dpd), a biochemical marker of bone resorp-
tion (Eyre et al., 1988), in the ob/ob mice argued againstcrease in osteoclastic bone resorption, or to a combina-
tion of both abnormalities. To study osteoblast function this hypothesis (wt: 10.5 6 2.5 nM Dpd/mM creatinine;
ob/ob: 24.0 6 4.0 nM Dpd/mM creatinine). To addressin vivo, the bone formation rate was quantified following
double labeling with calcein, a marker of newly formed this point more thoroughly, we took advantage of the
hypogonadism of the ob/ob mice. We reasoned thatbone (Figure 3A). In 3- and 6-month-old ob/ob mice,
there was a 70% and 60% increase, respectively, of the if the osteoclasts of the ob/ob mice were functional,
correcting their hypogonadism should decrease theirbone formation rate compared to that of wt littermates
(Figure 3B). This result demonstrated that the HBM phe- rate of bone resorption by diminishing the number of
osteoclasts and thereby further increasing their bonenotype of the ob/ob mice was due, at least in part,
to an increase in bone formation activity. Remarkably, mass. On the other hand, if the osteoclasts of the ob/
ob mice were not functioning properly, correcting theirconsidering the massive increase of the bone formation
rate, the osteoblasts surface as well as the osteoblast hypogonadism should not affect the severity of their
HBM phenotype. To determine which of these two possi-number were not increased in ob/ob mice, indicating
that leptin deficiency affects the function of the osteo- bilities was correct, estradiol or placebo pellets were
implanted subcutaneously in 2-month-old female ob/blasts, not their differentiation or proliferation after birth
(Figure 3C). The same observations were made in db/ ob mice; these animals were analyzed after a 3-month
treatment period.db mice (Figures 3D and 3E). As expected given the
existence of a hypogonadism, the number of osteoclasts As expected, the estradiol treatment corrected the
hypogonadism of these mice as judged by the aspectwas increased in both mutant mouse strains (Figure 3F),
suggesting that their HBM phenotype has developed of their uteri and their levels of estradiol in blood (Figure
4A and data not shown). It also led to a normalizationdespite an increase in bone resorption.
We ascertained the specificity of the effect of the of the osteoclast number and to a further increase of
Central Control of Bone Formation
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an assay using hematopoietic progenitor cells from wt,
ob/ob, or db/db mice and growth factors known to in-
duce the differentiation of these cells into functional
osteoclasts. As shown in Figure 4E, wt, ob/ob, and db/
db hematopoietic progenitor cells differentiated equally
well into osteoclasts able to resorb a matrix.
These experiments demonstrate that there is no de-
tectable functional defect of the osteoclasts in ob/ob
and db/db mice and establish that the HBM phenotype
of these mouse mutant strains results exclusively from
the increase in bone formation secondary to the ab-
sence of leptin signaling.
Absence of Leptin Signaling in Osteoblasts
Our analysis indicates that leptin is an inhibitor of osteo-
blastic bone formation. Moreover, the existence of an
HBM phenotype in db/db mice demonstrates that leptin
must bind to its known receptor to fulfill this function.
In theory, leptin could either act directly on osteoblasts,
indirectly through the release of a second factor present
in fat, or by using an hypothalamic relay as it does
for the control of body weight. We tested these three
possible mechanisms of action.
We could not detect any expression of Leptin in osteo-
blasts even after a long exposure, indicating that an
autocrine regulation was unlikely (Figure 5A). We also
could not detect any Leptin expression in whole bone
samples, providing an indirect argument against a para-
crine regulation of osteoblast function by leptin (Figure
5A). In any case, a paracrine and/or endocrine regulation
of osteoblast function by leptin would require that func-
tional leptin receptors are present on osteoblasts. There
are several transcripts of the leptin receptor but only
one, Ob-Rb, is thought to have signal transduction abil-
ity (Tartaglia et al., 1995; Chen et al., 1996; Lee et al.,
Figure 4. Normal Osteoclasts Function in Absence of Leptin Sig- 1996). The expression of this transcript of leptin receptor
naling is highly, although not strictly, hypothalamus specific.
(A±D) Comparative analyses of wt and ob/ob mice whose hypogo- RT-PCR experiments were performed to search for Ob-
nadism has been corrected by 17b-estradiol treatment (E2) or not Rb transcripts in primary osteoblasts and whole bone
corrected (P, placebo).
samples. In several experiments using a number of am-(A) Correction of the uterus atrophy of the ob/ob mice by the 17b-
plification cycles necessary to detect Ob-Rb transcriptsestradiol treatment.
(B±D) Histological analysis of vertebrae showing that 17b-estradiol in hypothalamus, we failed to detect Ob-Rb expression
treatment leads to a significant increase in bone trabeculae in 17b- in calvaria, long bone, and primary osteoblast cultures
estradiol±treated wt and even more in 17b-estradiol±treated ob/ob (Figure 5B).
mice (B and D). The increased bone volume is more pronounced in To determine whether or not leptin could transduce its
17b-estradiol±treated ob/ob mice than in treated wt mice compared
signal in osteoblasts, we treated serum-starved primarywith placebo-treated animals (D), as their number of osteoclasts is
osteoblasts isolated from wt mice with leptin. We moni-returned to a normal range (C). Gray bars, wt mice; black bars, ob/
ob mice; patterned bars, treated mice; solid bars, placebo control tored the phosphorylation of Stat3, a downstream ef-
mice. Asterisks indicate a statistically significant difference between fector of leptin signaling in its target cells (Tartaglia et
treated and untreated mice (p , 0.05). Error bars represent SEM. al., 1995; Baumann et al., 1996; Ghilardi et al., 1996;
(E) Normal differentiation and function of ob/ob and db/db osteo- Vaisse et al., 1996), and the expression of two immediate
clasts ex vivo. Marrow progenitors derived from wt, ob/ob, and db/
early genes whose transcription increases following lep-db mice differentiate equally well in TRAP positive (TRAP1) osteo-
tin treatment of target cells (Elmquist et al., 1997). As aclasts (upper panel and bottom line). There is also no difference in
their ability to form resorption pits on a dentin slice matrix (bottom positive control, we used oncostatin-M that also induces
panel). Stat3 phosphorylation and activates the expression of
the same immediate early genes in osteoblasts (Levy et
al., 1996). As shown in Figure 5C, treatment of osteo-the HBM phenotype of these mice compared to placebo
treated ob/ob mice (Figures 4B±4D). Similar results were blasts with Oncostatin-M induced Stat3 phosphoryla-
tion while leptin treatment did not. Several doses ofobtained in male ob/ob mice treated with testosterone
implants (data not shown). This finding excluded a de- leptin, physiologic and supraphysiologic, were used in
this experiment; all of them failed to induce Stat3 phos-fect of bone resorption as the origin of the HBM pheno-
type in ob/ob mice. Finally, the function of the osteo- phorylation (data not shown). Similarly, expression of
Tis11 and c-fos was quickly and transiently activatedclasts of ob/ob and db/db mice was studied in vitro in
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Figure 5. Leptin Does Not Signal in Osteo-
blasts
(A) Northern blot analysis of Leptin expres-
sion in tissues and primary cells (nonmineral-
izing (NM) osteoblasts, mineralizing (M) os-
teoblasts, and chondrocytes) (upper panel).
Leptin expression can be detected only in
fat tissues, even after overexposure. Gapdh
expression was used as an internal control
for loading (lower panel).
(B) Ob-Rb transcripts cannot be detected in
long bones, calvaria, and primary osteoblasts
by RT-PCR while this message is detected
in hypothalamus. Amplification of Hprt was
used as an internal control for cDNA quality
and PCR efficiency.
(C) Western blot analysis. Absence of Stat3
phosphorylation (phospho Stat3) upon treat-
ment of serum-starved primary osteoblast cul-
tures with leptin. Induction by oncostatin-M
(OSM) was used as a positive control. Immu-
nodetection of Stat3 shows that identical
amounts of proteins were analyzed.
(D) Northern blot analysis of immediate-early
gene expression (Tis11 and c-fos genes)
upon treatment of primary osteoblast cul-
tures with leptin or OSM. An immediate and
transient signal can only be observed in OSM-
treated cultures. Gapdh expression was used
as an internal control for loading (lower
panel). min., minutes of treatment.
(E) Ex vivo primary osteoblast cultures from
wt mice maintained in the absence (vehicle)
or presence of leptin. No effect on collagen
synthesis (upper panel, van Gieson staining)
or matrix mineralization (lower panel, von
Kossa staining) can be observed.
(F) Normal function of db/db osteoblasts in ex vivo culture experiments. No difference can be observed on collagen synthesis (upper panel,
van Gieson staining) or matrix mineralization (lower panel, von Kossa staining) between primary osteoblast cultures derived from wt and db/
db mice.
by oncostatin-M but not by leptin (Figure 5D). Lastly, white adipose tissue, which is the type of fat regulated
by leptin signaling, and they have dramatically reducedwe studied the effect of a long-term leptin treatment of
primary osteoblast cultures from wt mice on extracellu- amounts of inactive brown adipose tissue. They also
have a 20-fold reduction in leptin level (Moitra et al.,lar matrix synthesis and bone matrix mineralization. No
difference was observed when assessing collagen syn- 1998). Yet, A-ZIP/F-1 transgenic mice have the same
HBM phenotype due to an increase in osteoblast func-thesis or formation of mineralization nodules between
control and leptin-treated cultures (Figure 5E). tion found in ob/ob and db/db mice (Figure 6).
This experiment has two implications. First, it confirmsIf there is no functional leptin receptor on osteoblasts,
then wt and db/db osteoblasts should be undistinguish- that leptin deficiency, not high fat index, is responsible
for the HBM phenotype of the ob/ob and db/db mice.able in ex vivo culture. Indeed, for all the parameter
analysis, alkaline phosphatase staining, type I collagen Second, it demonstrates that fat is not a necessary relay
for the action of leptin on bone formation.production, and formation of mineralization nodules,
there was no difference between wt and db/db primary
osteoblast cultures (Figure 5F and data not shown). Bone Loss Following Intracerebroventricular
Infusion of Leptin in ob/ob and wt MiceTaken together, these results indicate that leptin action
on bone formation in the entire animal does not require We next addressed whether leptin binding to its hypo-
thalamic receptor could correct the HBM phenotype ofleptin binding to a receptor located on the osteoblasts.
the ob/ob mice as it can rescue their obesity phenotype.
We inserted pumps delivering either PBS or leptin (8High Bone Mass in Absence of Fat
To address the possibility that this action of leptin could ng/hr) into the third ventricle of ob/ob mice. This dose
has been shown to have no effect when administeredrequire the presence of fat, we made use of a transgenic
mouse model expressing, exclusively in adipocytes, a systemically (Halaas et al., 1997). To be as close as
possible of the biologic situation of the ob/ob mice, thedominant-negative protein termed A-ZIP (Moitra et al.,
1998). This dominant-negative protein abolishes DNA animals in which pumps were inserted were ovariecto-
mized to avoid any increase in bone mass due to thebinding of most B-ZIP transcription factors, a class of
transcription factors critical for adipocyte differentia- correction of their hypogonadism. The pumps were left
in place for 28 days. Classical histology showed thattion. As a result, the A-ZIP/F-1 transgenic mice have no
Central Control of Bone Formation
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Figure 6. Fat Tissue Is Not Required for the Appearance of a High
Bone Mass Phenotype
(A) Histological analysis of vertebrae of 6-month-old wt and A-ZIP/
F-1 transgenic mice that have no fat tissue. Both bone volume (B)
and bone formation rate (C) are increased in the transgenic mice.
Asterisks indicate a statistically significant difference between wt
and transgenic mice (p , 0.05). Error bars represent SEM.
the bone of leptin-treated mice but not of the PBS-
treated mice had regained a normal appearance (Figure
7A). Indeed, bone volume was significantly decreased
in leptin-treated mice (Figure 7A). We could not detect
Figure 7. Leptin and NPY icv Infusions Affect Bone Massany leptin in the serum of these animals using a specific
Histological comparison of vertebrae of 4-month-old ob/ob (A) andradioimmunoassay (data not shown). To determine if
wt (B) mice infused centrally (third ventricle) with PBS or leptin. Inleptin could affect bone mass in a physiologic situation,
both cases, leptin icv infusion induces a decrease in bone mass
we performed the same experiment in wt mice. Classical and bone volume. (C) Histological comparison of vertebrae of
histology showed bone loss in leptin-treated but not in 4-month-old wt mice infused centrally with PBS or NPY. NPY icv
infusion causes a decrease in bone mass and bone volume. Under-PBS-treated wt mice and histomorphometric analyses
lined numbers indicate a statistically significant difference betweenshowed that the bone volume was significantly de-
experimental and control groups of mice (p , 0.05).creased in leptin-treated mice (Figure 7B). In summary,
the effect of leptin intracerebroventricular (icv) infusion
on the bone mass of ob/ob and wt mice demonstrates wt mice should lead to an HBM phenotype. To our sur-
that control of bone formation is a central, leptin-depen- prise, icv infusion of NPY caused bone loss not bone
dent, function. gain (Figure 7C), indicating that leptin and NPY do not
antagonize each other's function in the control of bone
formation as they appear to do in body weight control.Leptin and Neuropeptide Y Do Not Have Antagonistic
Functions in the Control of Bone Formation This result suggests that leptin may use different sets
of mediators to control body weight and bone mass.The results presented above indicate that leptin is a
powerful inhibitor of bone formation that acts centrally.
One of the very few neuromediators for which there is Discussion
physiologic and genetic evidence that it affects leptin's
action on body weight is NPY (see Elmquist et al., 1999 This study demonstrates that leptin is a major regulator
of bone formation. It provides in vivo evidence for aand Inui, 1999 for review). Indeed, NPY neurons express
leptin receptors, NPY expression is increased in ob/ob central regulation of bone remodeling, thus establishing
a physiologic paradigm for a hormone affecting bonemice but blunted upon leptin administration, NPY icv
infusion in wt animals causes body weight gain, and mass. This paradigm should influence our understand-
ing of osteoporosis, as it indicates that it is, at leastNPY deficiency partially corrects the obesity phenotype
of the ob/ob mice (Erickson et al., 1996). Thus, we rea- partly, a central disorder. Our findings also identify leptin
as a molecular determinant whose absence can over-soned that if NPY was also in the leptin-dependent path-
way controlling bone formation, icv infusion of NPY in come the low bone mass phenotype caused by gonadal
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failure and hypercortisolism. Lastly, our study uncovers affect osteoblast function and reveals the central nature
of bone remodeling regulation.an unexpected discrepancy between the mechanisms
of action of leptin in the control of body weight and of Beyond its hypothalamic relay, what is the mode of
action of leptin? The low bone mass phenotype of pa-bone formation.
tients with panhypopituitarism (Kaufman et al., 1992)
together with the presence of multiple endocrine abnor-Leptin Is a Regulator of Bone Formation
malities that should favor bone loss in ob/ob and db/A myriad of abnormalities has been described in ob/ob
db mice argue against a classical pituitary relay for leptinand db/db mice besides obesity. These include, among
action on bone formation. The same appears to be trueothers, insulin resistance, diabetes, abnormal behavior,
for leptin's effect on body weight (Aschner, 1912; Elm-decreased immune function, and hypothermia (Ingalls
quist et al., 1999). In that case, leptin action could beet al., 1950). Leptin plays a major and specific role in
mediated through the autonomic nervous system (Inoueeach of these physiologic processes. Likewise, multiple
and Bray, 1977; Elmquist et al., 1999). Since multiplelines of evidence establish that the HBM phenotype of
lines of evidence indicate that NPY is partly involved inthe ob/ob and db/db mice is a direct consequence of
counteracting leptin's effect on body weight, we testedthe absence of leptin signaling, not of obesity. Indeed,
whether it could affect bone mass. Unexpectedly, icvthis phenotype precedes the appearance of obesity in
infusion of NPY led to a low bone mass phenotype, asob/ob mice and is not observed in other models of obe-
does leptin icv infusion in wt mice. This result is ofsity, while heterozygote leptin-deficient mice that are
critical importance because it suggests that leptin usesnot obese and A-ZIP/F-1 transgenic mice, which have
different pathways to control body weight and boneno white fat and a very low level of circulating leptin,
mass.both have an HBM phenotype. This phenotype is due
to an increase in bone matrix deposition by the osteo-
blasts, not to an increase of their number. Hierarchy of Pathways Controlling
Bone RemodelingAmong the multiple endocrine abnormalities of ob/ob
mice, one of them is hypercortisolism, a condition known Bone remodeling is classically thought to be regulated
by cell±cell interactions and cytokines acting in an auto-to induce bone loss by decreasing bone formation (Reid,
1997). Yet, despite this hypercortisolism and their hypo- crine or paracrine fashion. In light of this study, it ap-
pears that bone mass is also controlled by a centralgonadism that should favor bone resorption, the ob/ob
mice have an HBM phenotype. The fact that this bone pathway. This central regulatory pathway is of critical
importance since ob/ob and db/db mice have an HBMphenotype occurs in such unfavorable circumstances
and is present in heterozygous leptin±deficient animals in spite of hypercortisolism and hypogonadism. No other
known pathway can overcome these two osteoporosis-indicate that leptin's action on bone formation is not less
important physiologically than its role in body weight favoring conditions. This genetic observation should
lead us to propose new concepts to study bone remod-control.
eling and its disorders. By analogy with the emerging
knowledge regarding the control of bone resorption byBone Remodeling as a Central Function
several secreted molecules (Suda et al., 1999), it is likelyLeptin is a hormone secreted by adipocytes and controls
that leptin is only one of many circulating moleculesbody weight through a hypothalamic relay (see Spiegel-
affecting bone formation. How are these novel regula-man and Flier, 1996 and Friedman and Halaas, 1998
tory pathways and the classical autocrine/paracrine reg-for review). Several molecular, genetic, and physiologic
ulation contributing to bone remodeling? Conceivably,lines of evidence indicate that it uses a similar hypothala-
leptin and other secreted molecules could regulate bonemic relay to control bone formation by the osteoblasts.
mass by affecting the synthesis or the function of localFirst, the ob/ob and db/db mice both have the same
factors present in the bone microenvironment. Alterna-bone phenotype, indicating that leptin uses a similar
tively, these two pathways may act independently ofreceptor to control body weight and bone mass. The
each other. The distinction between these two possibili-absence of Leptin expression in osteoblasts rules out
ties will have to await the identification of the leptinan autocrine mechanism. Although Ob-Rb transcripts
downstream effectors.have been detected in immortalized osteoblastic cell
lines using a high number of amplification cycles
(Thomas et al., 1999), we were unable to detect this Obesity as a Protective Factor
Against Osteoporosistranscript in primary osteoblasts. The absence of Ob-
Rb transcripts in osteoblasts, the lack of evidence of How does our study relate to the observation that obe-
sity protects from bone loss in humans? This may ap-leptin signaling in osteoblasts together with the normal
behavior ex vivo of osteoblasts isolated from db/db mice pear in apparent contradiction with the fact that Leptin
expression and serum leptin levels are elevated in obeseindicate that the osteoblast is not the direct target of
leptin action on bone formation. The HBM phenotype humans compared to lean individuals (Maffei et al., 1995;
Considine et al., 1996). However, as is the case in typeof the A-ZIP/F-1 transgenic mice demonstrates that fat
tissue is not necessary for the regulation of bone forma- II diabetes patients who show insulin resistance (Moller
and Flier, 1991), it appears that obese individuals aretion by leptin. In contrast, continuous delivery of a small
dose of leptin in the third ventricle completely rescues resistant to the biologic effects of leptin (Caro et al.,
1996; Bjorbaek et al., 1998). This resistance may bethe bone phenotype of the ob/ob mice and leads to
bone loss in wt mice. This latter result demonstrates that due to a partial failure to transport leptin to the central
nervous system in obesity. Thus, given the state of leptinleptin binding to its hypothalamic receptor is sufficient to
Central Control of Bone Formation
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ml leptin (Sigma) or vehicle for 5 days. The presence of a collagen-resistance of obese patients, the observation that the
rich extracellular matrix and of mineralization nodules was assessedabsence of leptin signaling in mice leads to HBM pro-
by whole-mount staining of the cultures by the van Gieson and vonvides a molecular hypothesis to explain the protective
Kossa reagent (Ducy et al., 1999), respectively.
effect of obesity on bone mass in humans.
Our observation provides the first evidence for a Leptin Signaling Assays
RT-PCR analysis of Ob-Rb expression was performed on random-mechanism linking the control of bone mass with the
primed cDNAs using previously described specific primers (Fried-regulation of body weight and possibly gonadal func-
man and Halaas, 1998) for 27 cycles. Subconfluent primary osteo-tion. Besides the multiple physiologic questions raised
blast cultures from wt mice were maintained for 4 days in 10%by this study, the data suggest that pharmacological
FBS mineralization medium then switched to 0.5% for 2 days and
manipulation of the leptin pathway may be a novel thera- replaced daily. Medium was replaced 2 hr before a 20 min treatment
peutic approach to prevent and/or treat osteoporosis with 80 ng/ml leptin (Sigma) or 40 ng/ml Oncostatin M (R&D Diagnos-
tics) or vehicle. RNA extractions were performed using Triazolby stimulating bone formation.
(GIBCO). Northern blots were performed with 15 mg of total RNA
according to standard procedures. For Western blot analysis, cells
Experimental Procedures
were lysed, protein extracts were separated on a 7.5% SDS-PAGE
and blotted on nitrocellulose (Bio-Rad) for immunoblotting assay.
Animals
Analysis of Stat3 phosphorylation was performed using the Phos-
Breeders and mutant mice (C57BL/6J Lepob, C57BL/6J Leprdb,
phoPlus Stat3 (Tyr705) Antibody kit (New England Biolabs) ac-
C57BL/6J Ay/a) were purchased from the Jackson Laboratory. Gen-
cording to the manufacturer's instructions.
eration of A-ZIP/F-1 transgenic mice has been previously reported.
Genotyping was performed according to established protocols
Protein and Hormones Measurements
(Chua et al., 1997; Moitra et al., 1998; Namae et al., 1998). Animals
Deoxypyridinoline cross-links were measured in morning urines us-
were fed a regular diet (Purina #5001) or, when indicated, a high
ing the Pyrilinks-D immunoassay kit (Metra Biosystem). Creatinine
fat/high carbohydrate diet (Bio-serv #F3282).
values were used for standardization between samples (Creatinine
kit, Metra Biosystem). Serum levels of hormones were quantified by
Histologic and Histomorphometric Analyses radioimmunoassays using kits from Diagnostic system laboratories
Contact X rays were performed using a Faxitron (Phillips). Bone (17b-estradiol and IGF1), Linco (leptin), Nichols Institute Diagnostics
specimens were processed as described. Histological analyses (PTH), and ICN Biomedicals (T4 and corticosterone).
were performed on undecalcified sections stained with the von
Kossa reagent and counterstained with Kernechtrot (Amling et al., Intracerebroventricular Infusion
1999). Double-labeling technique has been described (Amling et al., Animals were anesthetized with avertin and placed on a stereotaxic
1999): calcein was injected twice at 8-day intervals, and animals instrument (Stoelting). The calvaria was exposed and a 0.7 mm hole
were killed 2 days later. Static and dynamic histomorphometric anal- was drilled upon bregma. A 28-gauge cannula (Brain infusion kit II,
yses were performed according to standard protocols (Parfitt et Alza) was implanted into the third ventricle according to the following
al., 1987) using the Osteomeasure Analysis System (Osteometrics, coordinates: midline, 20.3 AP, 3 mm ventral (0 point bregma). The
Atlanta). Statistical differences between groups (n 5 4 to 6) were cannula was secured to the skull with cyanoacrylate, and attached
assessed by Student's test. with Tygon tubing to an osmotic pump (Alza) placed in the dorsal
subcutaneous space of the animal. The rate of delivery was 0.25
ml/hr (8 ng/hr) of leptin (Sigma) or 0.5 ml/hr (75 ng/hr) of NPY (Sigma)Biomechanical Analysis
or PBS for 28 days.Femora were tested to failure by three-point bending on a servo-
hydraulic testing machine (Zwick GmbHandCo) at a constant dis-
Acknowledgmentsplacement rate of 10 mm/min (Amling et al., 1999). Failure load is a
measure of the strength of the bones.
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